Tabby Therapeutics


Tabby Therapeutics

2023 2023 Winner | Venture Winner Science Start-ups (Falling Walls Venture)

B cells have a significant role in the positive immune response affecting the outcome of cancer. Tabby Therapeutics is developing first-in-class novel engineered B cells (EBC) for tumor immunotherapy.

By introducing engineered B cell receptors (BCR) directed against tumor specific targets, they can exert multiple anti-tumor effects leveraging B cell unique capabilities to orchestrate humoral, cellular, adaptive and innate immune responses. Tabby’s EBCs offer a novel living and evolving tuned-medicine for the treatment of solid tumors.

Content by this speaker

Explore more content of Falling Walls

Events with Tabby Therapeutics

Tue | Nov 07, 2023 | 02.00 PM - 04.00 PM Berlin Time

Falling Walls Venture Pitches – Session 3: Health Solutions

Further Activities to have a look at